You just read:

Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

News provided by

Blueprint Medicines Corporation

Oct 28, 2019, 08:00 ET